Residual risk of HIV, HBV, and HCV transmission through blood transfusion in Borgou, Benin, 2023–2025 - Summary - MDSpire

Residual risk of HIV, HBV, and HCV transmission through blood transfusion in Borgou, Benin, 2023–2025

  • By

  • Kamel-Dine Djaliri

  • Adolphe Adjanohoun

  • Pamphile Aguessy

  • Victorien Dougnon

  • Haziz Sina

  • Lamine Baba-Moussa

  • June 4, 2026

  • 0 min

Share

Objective:

To estimate the residual risk of HIV, HBV, and HCV transmission among blood donors in the Borgou department of Benin, highlighting its importance for transfusion safety.

Key Findings:
  • Total of 11,113 repeat donors included, with a male predominance (male-to-female ratio: 14.14).
  • Majority of donors aged 18–30 years (72%) and students (54%).
  • Identified 145 incident infections: 5.98 for HIV, 350.28 for HBV, and 77.84 for HCV per 100,000 donor-years.
  • No significant association between HIV incidence and sociodemographic characteristics.
  • Significant associations for HBV and HCV incidences with age (p < 0.001 and p = 0.03, respectively).
  • Estimated residual risks: 1 in 277,000 donations for HIV, 1 in 1,862 for HBV, and 1 in 7,070 for HCV.
Interpretation:

Residual risk of TTIs in Borgou is lower than in several sub-Saharan African settings but higher than in high-income countries, indicating a need for improved public health policies.

Limitations:
  • Lack of robust epidemiological surveillance systems for blood donors.
  • Limited post-transfusion recipient follow-up, which may affect the accuracy of findings.
Conclusion:

Findings highlight the need to strengthen donor selection strategies, enhance health education, and implement more sensitive screening technologies, emphasizing the significance of these measures in improving blood safety.

Original Source(s)

Related Content